What's new? Log in Free sign up

Gracell Biotechnologies (GRCL) News and press releases

Company Profile

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Gracell Biotechnologies, Maintains $12 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Emily Bodnar reiterates Gracell Biotechnologies (NASDAQ:GRCL) with a Buy and maintains $12 price target.

Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)

Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell

Gracell Biotechnologies Q1 EPS $(0.07) Beats $(0.39) Estimate

Gracell Biotechnologies (NASDAQ:GRCL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.39) by 82.05 percent. This is a 80 percent increase over losses of $(0.35) per share

Earnings Scheduled For May 15, 2023

Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 345 companies set new 52-week lows.

Gracell Biotechnologies To Present Updated Clinical Data On BCMA/CD19 Dual-Targeting FasTCAR-T GC012F At 2023 ASCO Annual Meeting

Biotech, News, FDA, Events, General

Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 286 companies set new 52-week lows.

Wells Fargo Assumes Gracell Biotechnologies at Overweight, Announces Price Target of $7

News, Price Target, Initiation, Analyst Ratings

Wells Fargo analyst Yanan Zhu assumes Gracell Biotechnologies (NASDAQ:GRCL) with a Overweight rating and announces Price Target of $7.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gracell Biotechnologies Announced That It Entered Into A License Agreement With Seagen To Grant To Gracell Worldwide License To Certain Patent Rights That Seagen Owns

Gracell Biotechnologies, Inc.

Gracell Biotechnologies Q4 EPS $(0.06) Beats $(0.13) Estimate

Gracell Biotechnologies (NASDAQ:GRCL) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 80 percent increase over losses of $(0.30) per share

Gracell Biotechnologies's Earnings: A Preview

Press releases

From Benzinga Pro

Gracell Biotechnologies to Participate in Jefferies Healthcare Conference

News, Press Releases

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, May 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical

Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd

News, Press Releases

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 15, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly

Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update

Earnings, Press Releases

Presenting longer-term follow-up data from investigator-initiated trial (IIT) evaluating BCMA/CD19 dual-targeting FasTCAR-T GC012F in relapsed/refractory multiple myeloma (RRMM) at 2023 ASCO and EHA2023On track to

Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)

Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress

First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety profile for treatment of relapsed/refractory B-cell acute

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

News, Press Releases

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and

Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023

News, Press Releases

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 02, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical

Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022

SAN DIEGO and SUZHOU, China and SHANGHAI, China, April 25, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

News, Health Care, Press Releases

SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update

Earnings, Press Releases

Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the second quarter of 2023 after receipt of FDA clearance for

Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference

SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 28, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.